BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 29522280)

  • 21. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Value of Peripheral Blood miR-374b-5p in Patients with Prostate Cancer.
    Pang C; Song X; Fu C; Zhang Y; Zhang Y; Liu M
    Clin Lab; 2020 Jan; 66(1):. PubMed ID: 32013356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
    Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
    Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
    Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
    Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
    Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A circulating miRNA assay as a first-line test for prostate cancer screening.
    Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
    Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.
    Spahn M; Kneitz S; Scholz CJ; Stenger N; Rüdiger T; Ströbel P; Riedmiller H; Kneitz B
    Int J Cancer; 2010 Jul; 127(2):394-403. PubMed ID: 19585579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics.
    Wang H; Yang L; Mi Y; Wang Y; Ma C; Zhao J; Liu P; Gao Y; Li P
    Contrast Media Mol Imaging; 2022; 2022():6094409. PubMed ID: 35935308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
    Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
    Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study.
    Shafiee R; Shariat A; Khalili S; Malayeri HZ; Mokarizadeh A; Anissian A; Ahmadi MR; Hosseini E; Naderafif M; Mohsenzadeh S; Rasoulian MH; Rezapour R; Pourzaer M
    Tumour Biol; 2015 Apr; 36(4):2437-45. PubMed ID: 25420908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
    Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
    Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
    Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
    Rezatabar S; Moudi E; Sadeghi F; Khafri S; Kopi TA; Parsian H
    J Gene Med; 2020 Oct; 22(10):e3239. PubMed ID: 32529802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-Level Expression of microRNA-21 in Peripheral Blood Mononuclear Cells Is a Diagnostic and Prognostic Marker in Prostate Cancer.
    Huang W; Kang XL; Cen S; Wang Y; Chen X
    Genet Test Mol Biomarkers; 2015 Sep; 19(9):469-75. PubMed ID: 26247873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.
    Fawzy MS; Mohamed RH; Elfayoumi AR
    Med Oncol; 2015 Mar; 32(3):74. PubMed ID: 25698533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.